此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

美国的一项研究考察了 Pradaxa 颗粒对 3 个月至 12 岁以下儿童的安全性和有效性，这些儿童需要治疗血凝块或已经出现血凝块并有形成另一个血凝块的风险

2026年6月1日 更新者：Boehringer Ingelheim

Pradaxa 口服颗粒制剂在现实环境中治疗 3 个月至 12 岁以下儿科患者急性静脉血栓栓塞事件 (VTE) 和/或降低 VTE 复发风险的安全性和有效性：前瞻性非干预性研究在美国进行的研究

本研究的主要研究问题是在常规临床实践环境中获得 Pradaxa 颗粒在 3 个月至 12 岁以下儿童中的进一步安全性和有效性数据。

研究概览

地位

终止

条件

研究类型

观察性的

注册 (实际的)

5

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • California
      • La Jolla、California、美国、92093
        • University of California, San Diego
      • San Diego、California、美国、92123
        • Rady Children's Hospital
    • Connecticut
      • New Haven、Connecticut、美国、06519
        • Yale University School Of Medicine
    • Florida
      • St. Petersburg、Florida、美国、33701
        • Johns Hopkins All Children's Hospital
    • Indiana
      • Indianapolis、Indiana、美国、46260
        • Indiana Hemophilia & Thrombrosis Center
    • Ohio
      • Cincinnati、Ohio、美国、45229
        • Cincinnati Children's Hospital
      • Dayton、Ohio、美国、45404
        • Dayton Children's Hospital
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • MUSC (Medical university of South Carolina)
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • Vanderbilt University
    • Texas
      • Austin、Texas、美国、78723
        • Dell Children's Ascension

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子

接受健康志愿者

不

取样方法

非概率样本

研究人群

因静脉血栓栓塞事件（VTE）而可能考虑使用 Pradaxa 颗粒抗凝的 3 个月至 12 岁以下儿童患者通常在新生儿科、小儿普通外科、心脏外科或重症监护病房接受治疗。 使用 Pradaxa 颗粒进行抗凝治疗以预防复发性 VTE 的儿科患者通常由儿科血液病房的儿科血液科医生进行评估。 任何服用 Pradaxa 颗粒的患者都可以考虑纳入本研究。

描述

纳入标准：

  • 父母/护理人员的书面知情同意书以及患者的同意书（如果年龄合适）

  • 开始 Pradaxa 颗粒给药作为初始或后续治疗：

    • 静脉血栓栓塞事件（VTE）的治疗
    • 降低 VTE 复发风险的治疗

排除标准：

  • 不排除参与任何随机临床试验或使用研究产品、参与任何其他观察性研究
  • 根据美国处方信息，Pradaxa 颗粒有任何禁忌症。
  • 以前参与过这项研究。

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

队列和干预

团体/队列
Pradaxa-treated patients
Pediatric patients with acute venous thromboembolic events (VTE) and/or at risk of recurrent VTE due to the presence of unresolved clinical risk factors received Pradaxa Pellets orally, either according to the prescribing label or off-label.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Cumulative Incidence of Clinically Relevant Bleeding Events
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.

Cumulative incidence of clinically relevant bleeding events was reported as the number of participants with clinically relevant bleeding events, defined as the composite of major bleeding events (MBE) and clinically relevant non-major (CRNM) bleeding events, according to recommendations from international thrombosis and hemostasis committees.

MBE were defined as: fatal bleeding; clinically overt bleeding associated with a decrease in hemoglobin of at least 2 grams/deciliter in a 24-hour period; critical site bleeding; bleeding that required an intervention via invasive procedure; and overt bleeding for which a reversal agent was administered.

CRNM bleeding was defined as: overt bleeding for which a blood product was administered and did not meet the criteria for major bleeding; bleeding that resulted in a medical or procedural intervention not meeting major bleeding criteria, including a medication change; and bleeding that resulted in hospitalization or an increased level of care.
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.

次要结果测量

结果测量
措施说明
大体时间
Occurrence of Recurrent Venous Thromboembolic Event (VTE)
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
The occurrence of VTE is reported as the number of participants with recurrent VTE including both symptomatic and asymptomatic events. Symptomatic recurrent VTE is defined as radiologically-confirmed new venous thrombotic or embolic burden at least 7 days post-diagnosis of the index VTE, accompanied by signs and/or symptoms attributable to the new thromboembolism. Asymptomatic VTE was defined by new thrombotic/embolic burden as disclosed by comparison of end-of-treatment imaging versus baseline imaging of the vascular region involved by the index VTE.
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Mortality Related to Thrombotic or Thromboembolic Events
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Number of participants who died with thrombotic or thromboembolic events.
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Occurrence of All Bleeding Events
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.

The occurrence of all-bleeding events is reported as the number of participants experiencing any of the bleeding event described. All bleeding events were defined as the composite of major bleeding events (MBE), clinically relevant non-major (CRNM) bleeding events and minor bleeding events but not leading to hospitalization, increased level of inpatient care, or an intervention by the medical team.

Minor bleeding events were defined as any overt or macroscopic evidence of bleeding that does not fulfil the criteria for major bleeding, CRNM bleeding, or important bleeding without intervention according to recommendations from international thrombosis and hemostasis committees.
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Occurrence of Post-thrombotic Syndrome (PTS)
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Occurrence of post-thrombotic syndrome (PTS) is reported as the number of participants with PTS. The presence of PTS was evaluated by the Villalta Scale Modified for Children, the Manco-Johnson instrument, or other validated pediatric PTS instrument employed in routine clinical care, according to recommendations from international thrombosis and hemostasis committees.
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Incidence of Adverse Events (AEs)
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Incidence of adverse events is reported as number of participants with any adverse event (AEs).
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Incidence of Serious Adverse Events (SAEs)
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Incidence of serious adverse events is reported as number of participants with serious adverse event (SAEs).
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Thrombotic Burden at the End of Treatment
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Number of participants with thrombotic burden at the end of the treatment period compared to baseline was quantified by image-based resolution status of the thrombus at the discretion of the treating physician, based on the type and location of the initial diagnosis of the thromboembolism. When appropriate, the same approach used for the baseline evaluations was utilized.
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Recurrence of Venous Thromboembolic Event (VTE) While on Treatment
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Number of participants with new or recurrent VTE occurring at least 7 days after diagnosis of the VTE captured on the baseline VTE form (index VTE).
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Duration of Treatment With Dabigatran Etexilate
大体时间：From first Pradaxa Pellets exposure until its discontinuation. Up to 370 days.
The median duration of the dabigatran etexilate (Pradaxa Pellets) treatment is reported.
From first Pradaxa Pellets exposure until its discontinuation. Up to 370 days.
Compliance With Dabigatran Etexilate Treatment
大体时间：From first Pradaxa Pellets exposure until its discontinuation. At 6-week, 3-months, 6-month, and 12-month follow-up, and at unscheduled follow-up (up to 370 days).
Number of participants complying with dabigatran etexilate (Pradaxa Pellets) treatment. Compliance was defined as not missing 0-1 treatment dose since the last visit, as evaluated at each time point. Unscheduled follow-up was defined as patient contact in between any scheduled study visit.
From first Pradaxa Pellets exposure until its discontinuation. At 6-week, 3-months, 6-month, and 12-month follow-up, and at unscheduled follow-up (up to 370 days).
Incidence of Adverse Events Leading to Drug Discontinuation
大体时间：From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.
Incidence of adverse events leading to discontinuation of Pradaxa Pellets is reported as the number of participants.
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Boehringer Ingelheim

合作者

Children's Hospital Acquired Thrombosis consortium

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年4月19日

初级完成 (实际的)

2025年4月28日

研究完成 (实际的)

2025年4月28日

研究注册日期

首次提交

2023年7月21日

首先提交符合 QC 标准的

2023年7月21日

首次发布 (实际的)

2023年8月1日

研究记录更新

最后更新发布 (实际的)

2026年6月2日

上次提交的符合 QC 标准的更新

2026年6月1日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 1160-0309

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

一旦满足“时间范围”部分中的标准，研究人员可以使用以下链接 https://www.mystudywindow.com/msw/datasharing 请求访问有关本研究的临床研究文件，并签署“文件共享协议”。

此外，研究人员可以在提交研究计划后并根据网站中概述的条款请求访问本研究和其他列出的研究的临床研究数据。

IPD 共享时间框架

发布结构化结果后，在主要手稿被接受出版后，美国和欧盟的产品和适应症的所有监管活动均已完成。

IPD 共享访问标准

对于研究文件 - 签署“文件共享协议”后。

对于研究数据 - 1. 研究计划提交并获得批准后（申办者和/或独立审查小组将进行检查，包括检查计划的分析是否与申办者的发表计划不相冲突）； 2.并签署法律协议。

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅